<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shuman, Jill</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sarode, Ravi</style></author><author><style face="normal" font="default" size="100%">Dzik, Sunny</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Treating Anticoagulant-Associated Bleeding</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-10 10:58:07</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-27</style></pages><abstract><style  face="normal" font="default" size="100%">Agents that reverse the effect of vitamin K antagonists include plasma, vitamin K, and prothrombin complex concentrate. Hemostasis is most likely to be achieved by using a prothrombin complex concentrate. Guidelines for reversing the effect of direct-acting anticoagulants are based on guidelines that reflect the paucity of high-quality evidence.</style></abstract><number><style face="normal" font="default" size="100%">21</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>